The LEAPS Project of the MIT NEWDIGS initiative is actively soliciting Use Cases for our workstream focused on methods innovation associated with “Integrating Evidence Using Meta-Analytic Approaches.” This methodology is critical for the successful design, implementation, and scale-up of a novel Predictive Outcomes Platform (POP) now under development by the LEAPS community with the goal of improving patient outcomes in economically sustainable ways. 

NEWDIGS Leadership, with partners from the Tufts Clinical and Translational Science Institute (CTSI), have written a chapter in the upcoming publication: Broadly Engaged Team Science in Clinical and Translational Research (Springer International Publishing, 2022). The chapter, titled “Broadly Engaged Team Science Comes to Life in a Design Lab,” features the NEWDIGS Design Lab as a practical exemplar for the book’s main theme. The chapter describes ongoing experience in adapting Design Labs as we know them in FoCUS and LEAPS for application within NIH’s CTSI network of more than 50 medical research sites.

The book will be a resource on practical, sustainable, and effective diversity and inclusion initiatives in medical research, from team-building to patient advocacy to institutions, by using a range of real-life examples of strategy implementation, and how to engage a diverse team of scientific and stakeholder partners in research.  It features case studies and contributions drawn from basic science, clinical, translational, health policy, and social science research.  

Pre-orders available at https://www.springer.com/us/book/9783030830274

The LEAPS Project of the MIT NEWDIGS initiative is actively soliciting Use Cases for our workstream focused on methods innovation associated with “Integrating Evidence Using Meta-Analytic Approaches.” This methodology is critical for the successful design, implementation, and scale-up of a novel Predictive Outcomes Platform (POP) now under development by the LEAPS community with the goal of improving patient outcomes in economically sustainable ways. 

The Predictive Outcome Platform was conceptualized to address the need for a new capability for identifying clinically meaningful patient sub-populations of a target disease, and the associated predictive features that support the targeted use of drug therapy treatment regimens for optimal treatment outcomes. The platform will enable iterative cycles of predictive analytics applied by a network of federated evidence generation partners and coordinated by a neutral, centralized third party. It will be designed to scale efficiently, leveraging the sharing of evidence rather than patient-level data to refine the emergent predictive models.

Use Cases can come from any therapeutic area, though strong proposals focused on Rheumatoid Arthritis may be prioritized over others as we remain eager to leverage our work to date in this area. Key requirements for a use case include that the question being asked is predictive, it has real-world clinical importance, and it is relevant to multiple stakeholders.

Please download the Request for Use Case Nominations and the Nomination Form for a Use Case to advance our mutual priorities here! The deadline for submissions is October 15, 2021.